Current Oncology Reports

, 16:405 | Cite as

High-Grade Undifferentiated Sarcomas of the Uterus: Diagnosis, Outcomes, and New Treatment Approaches

  • Charles-André Philip
  • Patricia Pautier
  • Florence Duffaud
  • Isabelle Ray-CoquardEmail author
Gynecologic Cancers (NS Reed, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers


High-grade undifferentiated sarcomas (HGUS) are rare malignancies accounting for 6 % of all uterine sarcomas and have a very poor outcome. Histological classification of HGUS is currently debated as a subgroup with uniform nucleoli, and frequently YWHAE–FAM22 transcript has been described, constituting a potential target for new therapies. In localized HGUS, surgery involving total hysterectomy and bilateral oophorectomy is recommended. Adjuvant radiotherapy has recently been suggested in a retrospective study to decrease local recurrence and improve survival versus observation in localized HGUS. In metastatic or recurrent disease, chemotherapy with doxorubicin with or without ifosfamide constitutes the standard of care. Gemcitabine plus docetaxel also seems to be an interesting alternative. Targeted therapies such as pazopanib are now available for soft tissue sarcomas and so could be proposed for uterine sarcoma patients after first- or second-line chemotherapy in the metastatic phase. Further investigations are needed to determine their indications and targets. A European Organisation for Research and Treatment of Cancer (EORTC) randomized trial testing maintenance therapy with cabozantinib after first-line chemotherapy in HGUS is ongoing.


Undifferentiated endometrial sarcoma Endometrial stromal sarcoma High-grade endometrial sarcoma Uterine sarcoma Oncology 


Compliance with Ethics Guidelines

Conflict of Interest

Charles-André Philip, Patricia Pautier, Florence Duffaud, and Isabelle Ray-Coquard declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Echt G, Jepson J, Steel J, Langholz B, Luxton G, Hernandez W, et al. Treatment of uterine sarcomas. Cancer. 1990;66(1):35–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc'h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294. doi: 10.1371/journal.pone.0020294.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12(6):687–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14(5):415–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Malouf GG, Duclos J, Rey A, Duvillard P, Lazar V, Haie-Meder C, et al. Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann. Oncol. 2010;21(10):2002–6. doi: 10.1093/annonc/mdq064.
  6. 6.
    Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol. 1996;62(2):254–9. doi: 10.1006/gyno.1996.0224.PubMedCrossRefGoogle Scholar
  7. 7.
    Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32(8):1228–38. doi: 10.1097/PAS.0b013e31816a3b42.PubMedCrossRefGoogle Scholar
  8. 8.
    Hendrickson MR, Tavassoli FA, Kempson RL, et al. Mesenchymal tumours and related lesions. In: Tavassoli FA, Deville P, editors. World Health Organization classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. Lyon: IARC; 2003.Google Scholar
  9. 9.
    Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, et al. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol. 2010;23(2):225–34. doi: 10.1038/modpathol.2009.162.PubMedCrossRefGoogle Scholar
  10. 10.
    Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35(9):1364–72. doi: 10.1097/PAS.0b013e3182262743.PubMedCrossRefGoogle Scholar
  11. 11.
    Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004;95(3):583–7. doi: 10.1016/j.ygyno.2004.07.041.PubMedCrossRefGoogle Scholar
  12. 12.
    Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14(5):465–71. doi: 10.1038/modpathol.3880335.PubMedCrossRefGoogle Scholar
  13. 13.
    Nucci MR, O'Connell JT, Huettner PC, Cviko A, Sun D, Quade BJ. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25(4):455–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Reich O, Regauer S, Urdl W. Heterogeneous oestrogen- and progesterone-receptor expression in low-grade endometrial stromal sarcomas-implications for therapy. Eur J Cancer. 2000;36 Suppl 4:108.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee CH, Marino-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53. doi: 10.1097/PAS.0b013e31824a7b1a.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012;109(3):929–34. doi: 10.1073/pnas.1115528109.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535–58.PubMedCrossRefGoogle Scholar
  18. 18.
    Oliva E, Young RH, Amin MB, Clement PB. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26(4):403–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Larson B, Silfversward C, Nilsson B, Pettersson F. Endometrial stromal sarcoma of the uterus. A clinical and histopathological study. The Radiumhemmet series 1936-1981. Eur J Obstet Gynecol Reprod Biol. 1990;35(2–3):239–49.PubMedCrossRefGoogle Scholar
  20. 20.•
    Malouf GG, Lhomme C, Duvillard P, Morice P, Haie-Meder C, Pautier P. Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynaecol Obstet. 2013;122(1):57–61. doi: 10.1016/j.ijgo.2013.01.025. A retrospective study on 30 patients with UES showing outcomes of this pathology. Adjuvant radiation was the only factor correlated with improved PFS.
  21. 21.
    Leath 3rd CA, Huh WK, Hyde Jr J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105(3):630–4. doi: 10.1016/j.ygyno.2007.01.031.PubMedCrossRefGoogle Scholar
  22. 22.
    Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer. 1991;27(9):1095–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med. 2002;346(23):1832–3. doi: 10.1056/NEJM200206063462319.PubMedCrossRefGoogle Scholar
  24. 24.
    Trope CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51(6):694–705. doi: 10.3109/0284186X.2012.689111.PubMedCrossRefGoogle Scholar
  25. 25.
    Tamura R, Kashima K, Asatani M, Nishino K, Nishikawa N, Sekine M, et al. Preoperative ultrasound-guided needle biopsy of 63 uterine tumors having high signal intensity upon T2-weighted magnetic resonance imaging. Int J Gynecol Cancer. 2014;24(6):1042–7. doi: 10.1097/IGC.0000000000000189.PubMedCrossRefGoogle Scholar
  26. 26.
    ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii92–9. doi: 10.1093/annonc/mds253.Google Scholar
  27. 27.•
    Tanner EJ, Garg K, Leitao Jr MM, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127(1):27–31. doi: 10.1016/j.ygyno.2012.06.030. A retrospective study on 21 UES patients showing outocomes according to the stage of the disease and assessing docetaxel and gemcitabine in combination.
  28. 28.
    Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009;45(16):2818–24. doi: 10.1016/j.ejca.2009.06.030.PubMedCrossRefGoogle Scholar
  29. 29.
    Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii89–93. doi: 10.1093/annonc/mdn101.PubMedGoogle Scholar
  30. 30.
    Bartosch C, Exposito MI, Lopes JM. Low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma: a comparative analysis emphasizing the importance of distinguishing between these two groups. Int J Surg Pathol. 2010;18(4):286–91. doi: 10.1177/1066896909337600.PubMedCrossRefGoogle Scholar
  31. 31.
    Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;63(2):247–53. doi: 10.1006/gyno.1996.0314.PubMedCrossRefGoogle Scholar
  32. 32.
    Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210–5. doi: 10.1038/sj.bjc.6604527.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Garg G, Shah JP, Toy EP, Bryant CS, Kumar S, Morris RT. Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol. 2010;118(1):8–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Aubry MC, Myers JL, Colby TV, Leslie KO, Tazelaar HD. Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol. 2002;26(4):440–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Sciallis AP, Bedroske PP, Schoolmeester JK, Sukov WR, Keeney GL, Hodge JC, et al. High-grade endometrial stromal sarcomas: a clinicopathologic study of a group of tumors with heterogenous morphologic and genetic features. Am J Surg Pathol. 2014. doi: 10.1097/PAS.0000000000000256.PubMedGoogle Scholar
  36. 36.
    Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis Jr JL. Treatment of endometrial stromal tumors. Gynecol Oncol. 1990;36(1):60–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Gronchi A, Colombo C, Raut CP. Surgical management of localized soft tissue tumors. Cancer. 2014. doi: 10.1002/cncr.28715.PubMedGoogle Scholar
  38. 38.
    Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer. 1982;50(10):2170–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys. 2001;49(3):739–48.PubMedCrossRefGoogle Scholar
  40. 40.
    Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer. 2008;44(6):808–18. doi: 10.1016/j.ejca.2008.01.019.PubMedCrossRefGoogle Scholar
  41. 41.•
    Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24(4):1099–104. doi: 10.1093/annonc/mds545. One of the few prospective study in uterine sarcoma showing the benifit of doxorubicin based adjuvant chemotherapy combined with adjuvant pelvic radiation.
  42. 42.
    Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119(8):1555–61. doi: 10.1002/cncr.27942.PubMedCrossRefGoogle Scholar
  43. 43.
    Reichardt P. The treatment of uterine sarcomas. Ann Oncol. 2012;23 Suppl 10:x151–7. doi: 10.1093/annonc/mds359.PubMedCrossRefGoogle Scholar
  44. 44.
    Takano T, Niikura H, Ito K, Nagase S, Utsunomiya H, Otsuki T, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol. 2013. doi: 10.1007/s10147-013-0627-5.Google Scholar
  45. 45.
    Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler Jr WC, Creasman W, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985;55(8):1648–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992;166(2):556–9.PubMedCrossRefGoogle Scholar
  47. 47.•
    Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34. doi: 10.1016/j.ygyno.2008.03.010. A prospective study on metastatic LMS showing the interest of gemcitabine plus docetaxel in first line chemotherapy.
  48. 48.•
    Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):226–9. doi: 10.1006/gyno.1996.0220. A prospective study on advanced LMS showing the interest of doxorubicine plus or less ifosfamide in first line chemotherapy.
  49. 49.
    Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52(4):626–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Giuntoli 2nd RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106(1):82–8. doi: 10.1016/j.ygyno.2007.02.031.PubMedCrossRefGoogle Scholar
  51. 51.
    Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009;88(3):877–84. doi: 10.1016/j.athoracsur.2009.04.144. discussion 884-5.PubMedCrossRefGoogle Scholar
  52. 52.
    Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S, et al. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol. 2007;11(1):49–54. doi: 10.1016/j.anndiagpath.2006.03.012.PubMedCrossRefGoogle Scholar
  53. 53.
    van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. doi: 10.1016/S0140-6736(12)60651-5.PubMedCrossRefGoogle Scholar
  54. 54.
    Ray-Coquard I, Sleijfer S, Litière S, Blay J-Y, Le Cesne A, Van der Graaf WT. Pazopanib in uterine sarcoma (UtS): review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). J Clin Oncol. 2014;32(15 Suppl):10579.Google Scholar
  55. 55.
    Hensley ML, Miller A, O’Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, et al. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study. Gynecol Oncol. 2014;133(Supp 1):3. doi: 10.1016/j.ygyno.2014.03.022.CrossRefGoogle Scholar
  56. 56.
    Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol. 2001;13(4):261–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004;15(8):1261–6. doi: 10.1093/annonc/mdh309.PubMedCrossRefGoogle Scholar
  58. 58.
    Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308. doi: 10.1158/1535-7163.MCT-11-0264.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Charles-André Philip
    • 1
  • Patricia Pautier
    • 2
  • Florence Duffaud
    • 3
  • Isabelle Ray-Coquard
    • 1
    Email author
  1. 1.Department of Adult Medical OncologyCentre Leon BerardLyonFrance
  2. 2.Department of MedicineGynecology Unit, Gustave RoussyVillejuifFrance
  3. 3.Department of Medical OncologyCHU Timone-AdultesMarseilleFrance

Personalised recommendations